What Nanologica does

Nanologica AB (publ) is a Swedish life science company headquartered in Södertälje that develops, manufactures, and sells silica-based chromatography media for purification of pharmaceutical substances, with a core focus on peptide drugs including insulin and GLP-1 analogues such as Ozempic and Wegovy. The company's flagship product, NLAB Saga®, is a perfectly spherical, fully porous silica offering superior mechanical stability and chemical stability at high and low pH, optimized for large-scale preparative chromatography. The product line also includes NLAB® Idun, NLAB® Siv, and NLAB Saga® HPLC Columns. Products are sold in bulk through direct enterprise sales to pharmaceutical manufacturers, with a consultative sales cycle involving evaluation orders, application development projects, and production-scale qualification; the company also engages distribution partners in selected markets such as China.

Revenue is generated primarily through one-time bulk resin sales priced on a quote basis, with customers spanning the US, China, India, and Europe. The company listed on Nasdaq Stockholm Main Market under ticker NICA on 29 March 2022 and was founded in 2008.

In January 2026, Nanologica transformed its business model by acquiring Syntagon AB (formerly Ardena Södertälje AB), a contract development and manufacturing organization (CDMO) specializing in API production and development for small molecules and peptides, with approximately 45 employees and 2025 sales of around SEK 80 million. The acquisition was financed through directed share issues totaling SEK 13.7 million and a fully subscribed SEK 82.5 million rights issue completed in March 2026. The combined group now spans an integrated platform from early pharmaceutical development through commercial production and purification of drug substances, with approximately 70 employees group-wide. Strategic ownership is anchored by Flerie Invest AB at 49.7%, with CEO Andreas Bhagwani as the fourth-largest shareholder at 3.5%.

Name

Nanologica

Legal name

Nanologica AB (publ)

Website

https://nanologica.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Nanologica AB (publ) is a Swedish life science company developing silica-based chromatography media for purification of peptide drugs including insulin and GLP-1 analogues, sold to pharmaceutical manufacturers globally. Its 2026 acquisition of Syntagon AB added CDMO services for pharmaceutical substance development and manufacturing.

Ownership category

akta.pro rank

Product category

Pharmaceutical Chromatography Media

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Laboratory Analytical Instruments (3826), Pharmaceutical Preparations (2834)

akta.pro primary industry

Crystallization, Particle Engineering & Micronization Services (HLAGAHAJ)

akta.pro secondary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

Keywords

• Silica chromatography media
• Peptide drug purification
• Preparative chromatography
• Pharmaceutical contract manufacturing
• Insulin GLP-1 purification

Headquarters

HQ city

Södertälje

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. Chromatography Resin Sales: Nanologica develops, manufactures, and sells chromatography media (silica-based purification products) to pharmaceutical manufacturers. Products are sold in bulk quantities for use in peptide drug purification during pharmaceutical manufacturing. Revenue is generated through product sales with evaluation orders leading to production-scale orders.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Core offering

Nanologica develops, manufactures, and sells advanced silica-based chromatography media (NLAB Saga®, NLAB® Idun, NLAB® Siv, NLAB Saga® HPLC Columns) for purification of peptide drugs such as insulin and GLP-1 analogues. Products are sold in bulk to pharmaceutical manufacturers worldwide and are designed to deliver long lifetimes, high mechanical stability, and chemical stability across a broad pH range, lowering manufacturing costs and increasing productivity in peptide drug production. Through its January 2026 acquisition of Syntagon AB, the group also offers contract development and manufacturing (CDMO) services for pharmaceutical substances including small molecules and peptides.

Product overview

Nanologica is a Swedish life science group offering advanced chromatography products and contract manufacturing services for the pharmaceutical industry. The company's core product portfolio consists of NLAB Saga® (silica-based purification media for preparative chromatography), NLAB® Idun, NLAB® Siv, and NLAB Saga® HPLC Columns—all designed for purification of peptide drugs such as insulin and GLP-1 analogues. In January 2026, Nanologica expanded its capabilities through the acquisition of Syntagon AB (formerly Ardena Södertälje AB), a CDMO providing API development and manufacturing services, particularly in small molecules and peptides. This acquisition added approximately SEK 80 million in annual sales and 45 employees to the Group, creating an integrated platform from early development to commercial production of pharmaceutical substances.

Differentiator

Problem solved

Functional benefit

Brands

• NLAB Saga®: A new generation silica for preparative chromatography - perfectly spherical, fully porous silica with superior mechanical stability and exceptional chemical stability at high and low pH, optimized for large scale purification of peptides.
• NLAB® Idun
• NLAB® Siv
• Syntagon

Products and services

• NLAB Saga® A perfectly spherical, fully porous silica-based purification media with superior mechanical stability and exceptional chemical stability at high and low pH, designed for large-scale purification of peptide drugs such as insulin and GLP-1 analogues. Sold in bulk to pharmaceutical manufacturers to lower manufacturing costs and increase productivity.
• NLAB® Idun Chromatography resin product in the NLAB product line for pharmaceutical purification applications.
• NLAB® Siv Chromatography resin product in the NLAB product line for pharmaceutical purification applications.
• NLAB Saga® HPLC Columns HPLC columns utilizing NLAB Saga silica technology for analytical and preparative chromatography applications.
• Syntagon AB Contract Development and Manufacturing (CDMO) Contract Development and Manufacturing Organization (CDMO) specializing in API production and development, chemical engineering manufacturing, and process/analysis development for pharmaceutical raw materials, with core competence in small molecules and peptides and particular strength in purification and analysis of complex compounds. Serves pharmaceutical companies for clinical studies and commercial delivery.

Quantifiable outcome

• Can reduce manufacturing costs for pharmaceutical manufacturers through effective purification and long product lifetimes
• +2 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Ardena Sweden ABcoreStrategic or Co-development Partner · 29 January 2026Ardena Sweden sold its drug substance (API) site in Södertälje, Sweden to Nanologica. The acquired company was renamed Syntagon AB. Ardena became a shareholder in Nanologica through the acquisition and its CEO Jeremie Trochu joined Nanologica's Board of Directors. The companies intend to collaborate on joint customer projects and Ardena will continue to purchase services from Syntagon.
• Chinese Distribution PartnerminorChannel Partner/ Reseller/ Distributor · 22 October 2025New distribution partner in China engaged to sample NLAB Saga® to pharmaceutical manufacturers in order to reach more customers faster and expand market presence in China.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Others

• Recipharm: EQT-owned CDMO offering contract development and manufacturing of small molecules and peptides for pharmaceutical customers. Comparable to Syntagon, Nanologica's recently acquired CDMO subsidiary, in business model and customer base.

Direct peers

• Cytiva: Danaher-owned life sciences business and the global leader in bioprocessing chromatography resins (MabSelect, Capto) used in peptide and protein drug purification. Directly comparable to Nanologica in target customers, application, and product category.
• Tosoh Corporation: Japanese chemical company with a Separation & Purification division producing Toyopearl and TSK chromatography media for peptide and biopharmaceutical purification. Most direct competitor to Nanologica's NLAB Saga® in preparative chromatography for insulin and GLP-1 manufacturers.
• Merck KGaA (MilliporeSigma): Life Science arm of Merck KGaA selling Eshmuno and related chromatography resins for peptide and biopharmaceutical downstream processing. Overlaps directly with Nanologica's peptide purification media, with broader portfolio across lab products and bioprocessing.
• Purolite (Ecolab Life Sciences): Ecolab-owned resin manufacturer producing Chromalite, Praesto, and other chromatography media for peptide and oligonucleotide purification. Closely comparable to Nanologica's NLAB Saga® in target application and customer base.
• Avantor: Supplier of chromatography resins, columns, and bioprocessing consumables to pharmaceutical manufacturers. Direct competitor to Nanologica in the peptide and small-molecule purification media market.
• Phenomenex: Danaher-owned chromatography column and media manufacturer serving analytical and preparative chromatography applications including peptide drug purification. Comparable to Nanologica in chromatographic media offerings.
• Bio-Rad Laboratories: Life science tools company offering chromatography media (UNOsphere, Nuvia) and process chromatography solutions for peptide and protein purification. Direct competitor in the chromatography resin market serving pharmaceutical manufacturers.

Broad incumbents

• Sartorius AG: German bioprocess supplier offering chromatography resins and integrated downstream solutions as part of its bioprocessing platform. Adjacent to Nanologica's chromatography media business with a much broader scope.
• Thermo Fisher Scientific: Global life sciences incumbent offering POROS chromatography resins alongside instruments, columns, and broader bioprocessing solutions. Overlaps with Nanologica in peptide purification media but competes as part of a much larger portfolio.

Market position

Strengths2 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/nanologica
• LinkedInlinkedin.com/company/2404550

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanologica